Copaxone and Pregnancy: What Women with MS Need to Know
For women with relapsing-remitting multiple sclerosis (RRMS) planning a family, questions about medication safety during pregnancy and breastfeeding are paramount. Recent data and updated guidance offer reassurance regarding the use of Copaxone (glatiramer acetate) during both periods. Here’s a comprehensive overview of the latest information.
Understanding Copaxone and MS
Copaxone is a disease-modifying therapy (DMT) used to treat RRMS. It works by modulating the immune system, helping to reduce the frequency of relapses and slow the progression of disability. MotherToBaby provides further information about multiple sclerosis.
Copaxone Use During Pregnancy: Current Evidence
Extensive research now suggests that Copaxone does not pose a significant risk to developing fetuses. A study published in the journal Drug Safety, following mothers and their children for over four years, found no increased risk of birth defects at either the 20mg or 40mg doses. Research indicates pregnancy outcomes remained within normal ranges, and growth rates for breastfed infants were likewise within normal limits.
Analyses from the German MS and Fertility Register (DMSKW) of 151 pregnancies with Copaxone exposure and 95 without exposure showed no differences in first-trimester exposure regarding malformations, prematurity, or cesarean section. Neurology reports similar findings.
Teva Pharmaceuticals, the manufacturer of Copaxone, has also published data from its pharmacovigilance collection, examining over 2,455 pregnancies with known outcomes. This analysis also revealed no evidence of a safety risk for the course of the pregnancy or the newborn. Teva confirms these findings.
Copaxone and Breastfeeding
The good news extends to breastfeeding. The available data indicate that Copaxone can be safely used during lactation without apparent adverse effects on the infant. This allows women with MS to continue uninterrupted treatment even while breastfeeding.
Bridging Therapy with Copaxone
Copaxone offers a unique advantage: it can be used as a “bridge” to pregnancy. This means women can continue treatment while trying to conceive, preventing gaps in therapy if they stop contraception and their previous treatment due to pregnancy plans.
Important Considerations and Consultation
While the data is reassuring, it’s crucial to have an individualized risk-benefit assessment with your healthcare provider. They can discuss the benefits of continuing treatment versus the potential risks of untreated MS during pregnancy. Do not craft any changes to your medication regimen without consulting your doctor.
Copaxone Pregnancy Category
Copaxone is rated as Pregnancy Category B, indicating that animal reproduction studies have shown no evidence of harm to the fetus, but there are no adequate and well-controlled studies in humans. Teva Pharmaceuticals provides this information.
Key Takeaways
- Copaxone appears to be safe for use during pregnancy and breastfeeding.
- Extensive data from multiple studies support these findings.
- Copaxone can be used as a bridging therapy for women planning a pregnancy.
- Individualized risk-benefit assessment with a healthcare provider is essential.
The post Copaxone & Pregnancy: Updated Guidance for MS Treatment appeared first on Archynewsy.